[Federal Register Volume 64, Number 38 (Friday, February 26, 1999)]
[Notices]
[Page 9542]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-4755]



[[Page 9542]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 4, 1998, Novartis 
Pharmaceuticals Corp., 59 Route 10, East Hanover, New Jersey 07936, 
made application by renewal to the Drug Enforcement Administration 
(DEA) for registration as a bulk manufacturer of the Schedule II 
controlled substance methylphenidate (1724).
    The firm plans to manufacture finished product for distribution to 
its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, D.C. 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than April 27, 1999.

    Dated: February 5, 1999.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 99-4755 Filed 2-25-99; 8:45 am]
BILLING CODE 4410-09-M